Canadian Sec - Delayed Quote • CAD Izotropic Corporation (IZO.CN) Follow Compare 0.1950 +0.0300 +(18.18%) At close: January 17 at 3:00:31 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Izotropic Featured in Announcement of Research and Markets' U.S. Breast Cancer Analysis and Forecast - Company listed in Research and Markets' announcement and description of new research report on the U.S. Breast Cancer Screening and Diagnostic Market- - "U.S. breast cancer screening and diagnostic [device] market was valued at $1.55 billion in 2024 and is anticipated to reach $2.34 billion by the end of 2030, at a CAGR of 7.05% during the forecast period 2024-20301"--Report supports Company's regulatory strategy for IzoView Breast CT, reinforces high demand for new ... Izotropic Announces Team Leading Clinical Study Design and FDA Regulatory Submissions -New FDA Consultant is the former Director of the Division of Imaging, Diagnostics, and Software Reliability at the U.S Food and Drug Administration--New Biostatistical Consultant is the former Deputy Director of the Biostatistics and Data Management Center of the American College of Radiology Imaging Network, an NIH-funded cooperative that conducts clinical trials to evaluate the use of diagnostic imaging and image-guided treatments for cancer, has decades of successful experience in design and Izotropic Files Pre-Submission with U.S. FDA for Breast Cancer Screening -A screening indication for women with dense breast tissue adjunctive to 3D mammography increases the market size for annual IzoView scans by over 800%1 for initial approval and product launch- -Regulatory strategy responds to the "urgent call2" from the U.S. Preventative Services Task Force for solutions to finding breast cancers earlier in women with dense breast tissue--Comprehensive filing includes patient acquisition and clinical study plans that validate a projected clinical study timeline Izotropic Provides Update on Annual General Meeting Materials and Voting Procedures Vancouver, British Columbia--(Newsfile Corp. - December 4, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, announces that due to the suspension of mail service in Canada due to the nationwide strike of the Canadian Union of Postal Workers, that the notice of meeting, information circular, requests for financial statements and proxy form (the "Meeting Mat Izotropic Announces Regulatory Approval Plans to Launch Izoview for Breast Cancer Diagnostics in Patients with Dense Breasts in the U.S. and EU Vancouver, British Columbia--(Newsfile Corp. - August 23, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a breast CT (computed tomography) imaging system, is pleased to announce that it is pursuing a regulatory strategy in the U.S. and EU to launch IzoView as a diagnostic device indicated for use in patients with dense breast tissue, a normal variation associated with an increased risk for devel Izotropic Corporation Announces Closing of First Tranche of Non-Brokered Private Placement Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") - Further to the Company's news release of June 6, 2024, the Company is pleased to announce that it has completed the first tranche of its non-brokered private placement financing (the "Offering"), whereby the Company issued 1,800,000 units (each, a "Unit") at a price of $0.10 per Unit for gross proceeds of $180,000.00. ... Izotropic Corporation Announces Non-Brokered Private Placement Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, announced today that it intends to complete a small non-brokered private placement financing (the "Offering") of up to 3,000,000 units of the Company, (each a "Unit") at a price of $0.10 per each Unit for a gross proceeds of up to $300,000.00. ... Izotropic Receives Response From U.S. FDA Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, that produces images of anatomy for non-invasive characterization of tissue with an application in breast imaging, announces that further to its January 8th disclosure, it has received a response from the U.S. FDA. The FDA's mammogram and ultrasound Performance Overview Trailing total returns as of 1/17/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index Return IZO.CN S&P/TSX Composite index YTD +225.00% +1.82% 1-Year -7.14% +19.67% 3-Year -77.33% +17.37%